Inventor · disambiguated record
Edmund J. Moran
Also filed as: MORAN EDMUND J
47 granted patents·13 pending applications·1,441 citations·filing 1995–2023
99Inventor score
Files withTHERAVANCE INC33THERAVANCE BIOPHARMA R&D IP LLC11CHRISTENSEN BURTON G4HUGHES ADAM D3ONTOGEN CORP3
Top patents by PatentIndex Score
60 records- 0199US6693202B1Muscarinic receptor antagonistsTHERAVANCE INC·Filed 2000·Granted Feb 17, 2004·253 cites·11 claims
- 0299US6653323B2Aryl aniline β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2002·Granted Nov 25, 2003·100 cites·23 claims
- 0398US8691868B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2012·Granted Apr 8, 2014·57 cites·31 claims
- 0498US6670376B1Aryl aniline β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2002·Granted Dec 30, 2003·129 cites·40 claims
- 0598US6576793B1β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 2000·Granted Jun 10, 2003·115 cites·8 claims
- 0697US7341993B2Cross-linked glycopeptide—cephalosporin antibioticsTHERAVANCE INC·Filed 2005·Granted Mar 11, 2008·22 cites·2 claims
- 0797US6974797B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2002·Granted Dec 13, 2005·45 cites·25 claims
- 0896US7332471B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2006·Granted Feb 19, 2008·21 cites·23 claims
- 0996US7279458B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2006·Granted Oct 9, 2007·50 cites·12 claims
- 1096US6541669B1β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 1999·Granted Apr 1, 2003·114 cites·23 claims
- 1195US7067481B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2004·Granted Jun 27, 2006·41 cites·35 claims
- 1295US6747043B2Alkoxy aryl β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2003·Granted Jun 8, 2004·77 cites·30 claims
- 1395US6593497B1β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 2000·Granted Jul 15, 2003·56 cites·8 claims
- 1494US6713651B1β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 1999·Granted Mar 30, 2004·49 cites·9 claims
- 1593US6949568B2Aryl aniline β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2003·Granted Sep 27, 2005·23 cites·11 claims
- 1692US11484531B2Methods for treating chronic obstructive pulmonary diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Nov 1, 2022·5 cites·10 claims
- 1792US7067482B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2004·Granted Jun 27, 2006·43 cites·28 claims
- 1891US7662815B2Diaryl ether β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2007·Granted Feb 16, 2010·15 cites·16 claims
- 1991US6362371B1β2- adrenergic receptor agonistsADVANCED MEDICINE INC·Filed 1999·Granted Mar 26, 2002·61 cites·2 claims
- 2091US5770620AAryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitorsONTOGEN CORP·Filed 1995·Granted Jun 23, 1998·56 cites·27 claims
- 2190US10744104B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 18, 2020·2 cites·20 claims
- 2288US12016835B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Jun 25, 2024·0 cites·16 claims
- 2388US9682052B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2015·Granted Jun 20, 2017·4 cites·37 claims
- 2488US7317023B2Diaryl ether β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2005·Granted Jan 8, 2008·10 cites·18 claims
- 2587US10123984B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Nov 13, 2018·3 cites·10 claims
- 2687US7217738B2β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 2005·Granted May 15, 2007·6 cites·9 claims
- 2786US9150500B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2014·Granted Oct 6, 2015·5 cites·32 claims
- 2886US6683115B2β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 2001·Granted Jan 27, 2004·16 cites·24 claims
- 2985US7582765B2Aryl aniline β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2007·Granted Sep 1, 2009·2 cites·16 claims
- 3085US7125892B2Aryl aniline β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2003·Granted Oct 24, 2006·16 cites·4 claims
- 3183US12048692B2Methods for treating chronic obstructive pulmonary diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Granted Jul 30, 2024·0 cites·14 claims
- 3283US7871997B2Cephalosporin compoundsTHERAVANCE INC·Filed 2007·Granted Jan 18, 2011·1 cites·11 claims
- 3383US7105701B2β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 2005·Granted Sep 12, 2006·2 cites·9 claims
- 3482US12285417B2Methods for treating chronic obstructive pulmonary diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Granted Apr 29, 2025·0 cites·16 claims
- 3582US6919482B2β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 2004·Granted Jul 19, 2005·13 cites·10 claims
- 3676US11547687B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jan 10, 2023·0 cites·20 claims
- 3776US2023103691A1Methods for treating chronic obstructive pulmonary diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Application pending·0 cites
- 3874US7553971B2Aryl aniline β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2006·Granted Jun 30, 2009·1 cites·14 claims
- 3974US7173039B2Protein kinase inhibitorsTHERAVANCE INC·Filed 2005·Granted Feb 6, 2007·1 cites·9 claims
- 4074US6750241B2Protein kinase inhibitorsTHERAVANCE INC·Filed 2002·Granted Jun 15, 2004·5 cites·13 claims
- 4172US6916961B2β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 2002·Granted Jul 12, 2005·3 cites·8 claims
- 4267US6355805B1β3-adrenergic receptor agonistsADVANCED MEDICINE INC·Filed 1999·Granted Mar 12, 2002·14 cites·5 claims
- 4367US2009306134A1Muscarinic receptor antagonistsAGGEN JAMES·Filed 2008·Application pending·0 cites
- 4466US2008269344A1Beta2-Adrenergic Receptor AgonistsMORAN EDMUND J·Filed 2008·Application pending·0 cites
- 4566US2009111737A1Novel antibacterial agentsCHRISTENSEN BURTON G·Filed 2008·Application pending·0 cites
- 4665US7427639B2β2-adrenergic receptor agonistsTHERAVANCE INC·Filed 2007·Granted Sep 23, 2008·0 cites·4 claims
- 4762US2007154948A1Novel antibacterial agentsCHRISTENSEN BURTON G·Filed 2006·Application pending·0 cites
- 4862US2025288561A1Nezulcitinib for delivery by nebulized oral inhalationTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Application pending·0 cites
- 4961US7456203B2Muscarinic receptor antagonistsTHERAVANCE INC·Filed 2003·Granted Nov 25, 2008·1 cites·14 claims
- 5061US6528324B1Apparatus for pre-determined mass sorting of positional-encoded solid phase synthesis supportsONTOGEN CORP·Filed 2000·Granted Mar 4, 2003·4 cites·10 claims
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Edmund J. Moran files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →